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Introduction
Psychological therapies have more than three decades of his-
tory as empirically tested interventions for gastrointestinal
(GI) disorders. The principal reason for this is long-standing
recognition of substantial involvement of various psychoso-
cial influences in gastrointestinal health problems. This is best
established for the functional GI disorders (which are now
also called disorders of gut-brain interaction), a group of more
than thirty conditions that have in common that they have no
identifiable structural, biochemical, or infectious causes,
whereas intestinal functioning and visceral perception are dis-
turbed [1]. A large literature has documented association of a
range of psychological factors with symptom severity, poorer
outcomes, and quality of life impairment in these disorders.
They include elevated life stress, anxiety and depression, sex-
ual and physical trauma history, maladaptive psychological
and behavioral coping styles, and somatization [2–4]. These
psychosocial factors have also been reported to affect symp-
toms and well-being in organic GI disorders such as inflam-
matory bowel disease [3•, 5, 6].
In recent years, the means by which these psychological
and social factors affect the gut are gradually becoming clear-
er, as appreciation has rapidly grown of the important role of
the brain-gut axis—a complex two-way communication path-
way between the central nervous system and the enteric ner-
vous system consisting of neural, endocrine, and immune sig-
nals. The central nervous system not only perceives what is
happening in the gut, but actively and continually exerts
tuning influences to help maintain homeostasis and adapt
gut functions to the shifting demands of daily activity.
Stress-related disruption of that regulating activity, and espe-
cially when stress becomes chronic, can either lead to or ex-
acerbate GI symptoms. High levels of stress or intensely up-
setting emotional experiences can alter brain-gut regulation in
a number of ways, as brain regions involved with threat ap-
praisal and negative emotions become more involved in
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Abstract
Purpose of Review To review the nature, current evidence of efficacy, recent developments, and future prospects for cognitive 
behavioral therapy (CBT) and gut-directed hypnotherapy, the two best established psychological interventions for managing 
gastrointestinal (GI) disorders.
Recent Findings New large randomized controlled trials are showing that cost-effective therapy delivery formats (telephone-
based, Internet-based, fewer therapist sessions, or group therapy) are effective for treating GI disorders.
Summary CBT and hypnotherapy can produce substantial improvement in the digestive tract symptoms, psychological well-
being, and quality of life of GI patients. However, they have long been hampered by limited scalability and significant cost, and 
only been sufficiently tested for a few GI health problems. Through adoption of more cost-effective therapy formats and 
teletherapy, and by expanding the scope of efficacy testing to additional GI treatment targets, these interventions have the 
potential to become widely available options for improving clinical outcomes for patients with hard-to-treat GI disorders.
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cortical interpretation and reactions to signals from the gut.
This can amplify visceral perception, disturb GI motility, alter
intestinal secretion, increase intestinal permeability, and im-
pair blood flow and self-healing processes of the intestinal
mucosa. [3•, 7, 8] Additionally, it is now recognized that the
microbiome is an active player in brain-gut dysfunction.
Prolonged stress can contribute to dysbiosis that may affect
various gut functions directly and also have deleterious effects
on mood and stress reactions in the brain, which in turn can
undermine the brain’s normal regulation of gut perception and
gut functioning. [9, 10]
Supportive evidence for dysfunction in the brain’s regula-
tion of gut perception and gut activity in functional GI disor-
ders has been documented in multiple brain imaging studies.
This body of research has demonstrated [8, 11] that patients
with IBS tend to have elevated neural activity compared to
control subjects in brain regions involved in emotional arousal
(the amygdala and parts of the anterior cingulate cortex) and
pain perception (the midbrain cluster), but also reduced activ-
ity in other parts of the brain that handle cognitive modulation
of perception of intestinal stimuli. Furthermore, deficits in the
brain’s descending inhibition of pain signals have been report-
ed in substantial proportions of patient samples with IBS and
functional dyspepsia [8].
The compelling and growing evidence that dysfunction of
the brain-gut axis plays a major role in many GI disorders
makes targeted psychological interventions logical methods
to help restore normal brain processing of signals from the
viscera and to facilitate resumption of healthy central nervous
system regulation of gut functions such as secretion and mo-
tility. Consequently, psychological treatments for GI prob-
lems are now viewed as brain-gut therapies, and they have
proven useful for that purpose in a substantial body of empir-
ical literature. These treatments can also be used to improve
coping with chronic symptoms, enhance effective self-
management of illness, and address stigma related to gastro-
intestinal symptoms.
A broad range of different psychological treatments have
been evaluated in published research as brain-gut therapies for
various GI disorders. Among the ones that have been tested
and shown promise for improving GI symptoms in multiple
randomized controlled trials are relaxation training, psycho-
dynamic therapy, mindfulness training, cognitive behavioral
therapy and gut-directed hypnotherapy, as well as multi-
modal combinations of these interventions.
There is no clear evidence that any particular type of brain-
gut psychotherapy is more effective than others. They have
rarely been tested side by side in the same trials, and when
they are compared in meta-analyses, they tend to exhibit sim-
ilar effect sizes [12••, 13•, 14•]. However, two particular ther-
apy modalities, cognitive behavioral therapy (CBT) and hyp-
notherapy, have emerged as the leading psychological thera-
pies in GI treatment overall, in terms of both the amount of
empirical research that supports their effectiveness and the
extent to which they have been applied in practice by GI-
specialized mental health professionals. Those two therapy
modalities continue to be very actively researched, with new
and often parallel developments emerging year by year. They
have become the two key tools in the intervention toolbox of
empirically informed practice of psychogastroenterology [15].
Therefore, these two therapies will be the focus of this review.
We will discuss their nature as applied to GI disorders, the
current status of their empirical support in regard to different
GI disorders, recent developments in research on them, and
their future prospects and needed priorities. We will limit the
scope of our review to applications of these two therapies in
adults, as the pediatric gastrointestinal disorders have been
recently reviewed in this journal [16].
The Nature of the Therapies
Cognitive behavioral therapy is among the most widely used
of all forms of psychological treatment in the current practice
of clinical psychology, and also the one that has been investi-
gated most as an intervention for GI disorders. CBT is not a
single type of treatment but a class of multi-component ther-
apies that may include different constellations of treatment
elements based on the cognitive behavioral theoretical model.
The foundation of all CBT interventions focuses on the rela-
tionship between thoughts, emotions, behaviors, and physical
symptoms (see Fig. 1). CBT treatment, therefore, focuses on
identifying and changing unhelpful thoughts and/or behavior
to achieve improvement in symptoms, mood, and life func-
tioning. Typical components of this therapy as applied to GI
disorders include (a) education about the empirical basis and
rationale for CBT, the bi-directional role of stress in GI disor-
ders, and the brain-gut axis; (b) relaxation training, where
patients learn and practice methods such as diaphragmatic
breathing or progressive muscle relaxation to lower autonom-
ic arousal and neutralize stress; (c) cognitive restructuring,
which involves learning to adopt a more balanced and realistic
perspective through systematic monitoring, analysis, and cor-
rection of biased thinking that exacerbates symptoms and
maintains distress and discomfort; (d) coping skills training,
which aims to replace maladaptive or counter-productive
ways of handling challenges with more productive psycholog-
ical strategies and behavioral responses; and (e) exposure
techniques to help patients to deliberately engage what is
feared to overcome fear-based avoidance that often produces
life impairment and worsens emotional distress associated
with the GI disease. A key aspect of the therapy process is
homework assignments, where patients practice skills and sys-
tematically write down observations and make analyses as
taught in the sessions with the therapist. The therapy course
is commonly limited to 6–12 sessions, with additional “boost-
er” sessions as needed after completing therapy.
Gut-directed hypnotherapy is a form of treatment that relies
on a special mental state, hypnosis, which is induced with the
help of verbal guidance from the therapist in order to facilitate
receptivity to therapeutic suggestions. The hypnotic state can
be induced in a variety of ways, but typically this includes
guided physical relaxation, narrowing of the focus of atten-
tion, activation of vivid mental imagery, encouraging the pa-
tient to let things happen by themselves, and promoting men-
tal dissociation from the here-and-now. Once the patient is in
this state of heightened receptivity, the therapist first proceeds
with deepening techniques to further enhance this receptive
state and then delivers post-hypnotic suggestions to facilitate
specific changes in emotions, thoughts, and physical symp-
toms that will take place after the hypnotic state is terminated.
These suggestions are commonly accompanied by imagery
and metaphors that illustrate and reinforce the desired thera-
peutic changes. The post-hypnotic suggestions used in GI
treatment commonly aim to reduce frequency and intensity
of pain and discomfort, normalize bowel activity, decrease
the reactivity of the gastrointestinal tract to life stress, and
increase the patient’s overall sense of physical well-being.
Home practice with hypnosis audio recordings in between
sessions with the therapist is a common practice. As with
CBT, hypnotherapy for GI disorders is typically delivered in
a course of 6 to 12 sessions with a therapist.
Although CBT and hypnosis may seem very different, they
have many commonalities in the way they are utilized for
gastrointestinal disorders. As described above, they both in-
volve a brief and time-limited course of therapy, and employ
home practice in between therapist visits (see Table 1). They
are both structured interventions which are empirically
grounded in large bodies of research, and in many cases close-
ly follow empirically tested intervention protocols. Both inter-
ventions are suited for patients with a similar general set of
characteristics (see Table 2). Moreover, both therapies aim at
addressing the GI disorders they target in holistic ways by
Fig. 1 The Five Areas model of
CBT. CBT focuses on the
relationship between four
interactive areas of a person’s
functioning (rounded boxes), and
these are also influenced by the
current life situation. As indicated
in the figure, GI applications of
CBT commonly address three of
these areas of functioning directly
by means of specific intervention
techniques, and this in turn often
leads to improvements in the
fourth one (emotions) as well
Table 1 Examples of typical therapy formats for CBT and hypnotherapy in the treatment of GI disorders
Typical CBT format Typical gut-directed hypnotherapy format
Session 1:
• Education and rationale of the treatment
• Introduction to the role of the brain-gut axis in symptom experience
Sessions 2–9:
• Initial skill: Building insight into maladaptive or unhelpful cognitions
related to symptoms
• Advanced skill: Learning cognitive reframing
• Initial skill: Identifying unhelpful behaviors
• Advanced skills: Exposure techniques and coping skills
• Initial skill: Learning relaxation techniques
• Advanced skill: Practicing relaxation exercises at home and in stressful
moments
Session 10:
– Review of strengths/skills learned
– Plan for handling future symptom flares
Follow-up or “booster” sessions as needed
Session 1:
• Education and rationale of the treatment
• Introduction to the role of the brain-gut axis in symptom experience
Sessions 2–8:
• Hypnotic induction
• Extended physical relaxation and guided deepening of the hypnotic state
• Hypnotic verbal suggestions and therapeutic imagery/metaphors
• Re-alerting/waking from hypnosis
Home practice with a short hypnosis audio recording 5 days a week in
between therapy visits
Follow-up or “booster” session about 3 months after end of the therapy
course
changing thoughts, emotions, and the patients’ subjective ap-
praisal of, and reactivity to, the physical symptoms. Both of
them have shown evidence in brain imaging studies of nor-
malizing cortical reactions to visceral stimuli induced experi-
mentally in balloon inflation tests [17, 18].
A further similarity between these two chief brain-gut psy-
chotherapies is that they have generally been tested for the
same few GI disorders—at least where the level of inquiry
has extended to randomized controlled trials—and they seem
to have broadly comparable effects on those disorders.
However, for all GI disorders except IBS, the amount of evi-
dence that has accumulated from RCTs is greater for CBT
than for hypnosis.
Empirically Supported Areas of Application
Irritable Bowel Syndrome IBS is a common functional GI
disorder, affecting 4–5% of the adult population when defined
with Rome IV criteria [19]. This chronic condition of recur-
rent abdominal pain associated with abnormalities in bowel
functioning is a major focus of GI healthcare in gastroenter-
ology and primary care. Present pharmacotherapy options of-
fer relatively modest benefits in IBS [20], leaving many pa-
tients dissatisfied [21•] and in need of alternative treatment
options. IBS is the GI disorder where prominent involvement
of psychosocial factors and brain-gut dysfunction is most
firmly established, and also the one where psychological
brain-gut interventions have been tested most by far.
Consequently, enough evidence has accumulated to allow au-
thoritative reviewswith firm conclusions about the therapeutic
impact. A pair of recent systematic reviews and meta-analyses
of RCTs in this domain by Laird and colleagues [13•, 14•]
concluded that psychological treatments overall have a thera-
peutic effect of medium size on IBS symptoms that lasts at
least a year post-treatment, and that besides improvement in
bowel symptoms, the therapies afford patients significant im-
provement in mental health and daily life functioning. A sep-
arate systematic review and meta-analysis by Ford et al. [12••]
similarly found psychological treatments to be effective for
improving IBS, with a collective number needed to treat of 4
(indicating howmany patients must be treated in order for one
patient to receive benefit).
CBT has been tested in more than 20 randomized controlled
trials for IBS [13•, 22, 23••] and hypnotherapy in a dozen such
RCTs [24, 25]. In addition, there are numerous other published
research studies of each therapy in IBS, such as uncontrolled or
non-randomized pilot studies, mechanistic research, and large
consecutive case series documenting outcomes systematically.
Both interventions have exhibited superior outcomes in the
majority of controlled trials compared to a variety of control
conditions against which they have been tested, including usual
medical care, education, waiting-list for treatment, placebo
pills, antidepressant and antispasmodic medications, and sup-
portive talk therapy. Success rates have varied greatly, but the
majority of treated patients improve on the primary outcomes in
most studies testing either of these therapy modalities. This is
impressive considering that many of the studies have been con-
ducted specifically on groups of patients who have already
proven refractory to typical medical treatments. Benefits of
both the therapies are generally well maintained 6 and
12 months after end of treatment in IBS treatment without
further intervention, and the few studies that have tracked out-
comes longer indicate that the therapeutic effects last much
longer than those for many patients: for 18 months [26, 27], 2
years [28], or even up to 5 years [29] post-treatment.
Functional Dyspepsia Functional dyspepsia (FD), an upper GI
disorder involving epigastric pain or burning sensations, un-
comfortable fullness, and early satiety, is an even more com-
mon functional gastrointestinal disorder than IBS, with a pop-
ulation prevalence of 8–12% according to the Rome IV
criteria [30]. It has many similarities to IBS, as it has been
found to involve visceral hypersensitivity, is characterized
by both GI pain or discomfort and disturbed motility, and is
associated with multiple psychosocial factors in much the
same way as IBS [31]. Also like IBS, treatment is challenging
and leaves large proportions of patients without satisfactory
relief. Nomedication is approved specifically for this disorder,
and no medications exhibit high rates of success [32]. For all
of these reasons, it would seem that FD would be a natural
major target of investigations of psychological brain-gut ther-
apies. However, it has been neglected in such research. Only
two randomized controlled trials of FD treatment with CBT
have been published, 20 years apart, as well as a single hyp-
notherapy trial. The largest of these studies was a Spanish
study [33•] of 158 consecutive FD patients that found that a
10-session course of coping-focused CBT sessions, delivered
Table 2 Patient characteristics indicative of good suitability for
psychological brain-gut therapies
Has moderate or severe gastrointestinal symptoms that have not
responded adequately to usual medical interventions
Is accepting the idea of using psychological methods to improve GI
symptoms via the brain-gut axis
Reports that the GI symptoms are adversely affected by life stress
Has GI symptoms that interfere significantly with important areas of life
functioning
Has been conclusively diagnosed by a physician with a GI disorder for
which brain-gut psychotherapy is applicable
Does not have current untreated psychiatric conditions causing high
levels of emotional distress (e.g., major depression, bipolar disorder,
PTSD, substance abuse)
Will be able to attend weekly or bi-weekly therapy visits for 2–3 months
Willingness to complete practice or “homework” between visits with the
therapist
largely in group format, resulted in improved dyspepsia symp-
toms and quality of life compared to medical care alone. The
improvements in the CBT group were well-maintained at 6-
month follow-up. The other CBT trial was conducted on 100
FD patients in Sweden [34] receiving either 10 sessions of
CBT or no treatment, and reported significant improvement
in FD symptoms and psychological well-being from CBT that
remained after 1 year.
The only hypnotherapy RCT in this patient population [35]
involved 126 patients and similarly demonstrated strong ad-
vantages of brain-gut therapy. FD patients assigned to 12 ses-
sions of hypnotherapy showed significantly greater dyspepsia
symptom reduction and more improvement in quality of life
than those in two comparison groups treated with supportive
talk therapy or with antacid medication (ranitidine). These
group differences were even more pronounced at 8-month
follow-up.
Based on the universally positive findings in this small set
of studies, it seems almost certain that these two brain-gut
therapies can make a substantial difference in FD care and
provide much needed improvement in clinical outcomes.
However, additional trials should be conducted to establish
their efficacy more firmly.
Non-cardiac Chest Pain Non-cardiac chest pain is a recurrent
retrosternal angina-like pain of presumed esophageal origin,
which is sometimes associated with gastroesophageal reflux
[36]. It is a very common health problem—experienced ac-
cording to some estimates by one in every four adults at some
point. It is challenging to treat with conventional medical ap-
proaches and is commonly distressing to patients and costly to
evaluate due to the cardiac-like and ambiguous nature of the
symptoms. Clinical efficacy of CBT has been evaluated in six
RCTs in this disorder [37–42]. Five of them achieved signif-
icantly superior symptom improvement over control groups,
which were most commonly patients assigned to usual medi-
cal care, but otherwise waiting-list controls (one study) or
patients given anxiety medication or placebo pills (one study).
Four of those studies found the CBT intervention to improve
both chest pain and psychological symptoms [37–40], where-
as one improved only fear of body sensations and quality of
life [41]. These predominantly positive results strongly indi-
cate that this form of therapy can be of value in this difficult
and costly disorder.
Hypnotherapy has only been tested in a single, small, ran-
domized trial [43] of 28 patients as therapy for non-cardiac
chest pain, where the control group received supportive talk
therapy and placebo medication. Hypnotherapy proved more
efficacious than the control intervention in terms of pain and
general well-being, with 80% of patients in the hypnosis
group vs. 23% in the control group showing at least moderate
improvement in pain. Those outcome differences were fully
maintained at a 2-year follow-up [44].
Inflammatory Bowel Disease Inflammatory bowel disease
(IBD), which encompasses both Crohn’s disease and ulcera-
tive colitis, is a health problemwith less than 1% prevalence in
the population [45, 46]. It is characterized by inflammation in
the lining of the intestines, with symptoms that can include
abdominal pain, diarrhea, weight loss, and fatigue. It is the
only type of organic GI disorders for which psychological
treatments have been tested to a significant extent. Here,
CBT has been the principal therapy investigated. A recent
systematic review and meta-analysis [47•] identified seven
randomized controlled CBT trials in this domain. Five of the
trials tested interventions in mixed groups of patients with
Crohn’s disease and ulcerative colitis, while one included only
Crohn’s patients and one only ulcerative colitis patients. The
reviewers concluded based on their meta-analysis that CBT
improves quality of life in IBD, whereas there is no evidence
that the therapy has an effect on disease activity. However, it
should be noted that there is growing awareness of IBS and
IBD overlap, in which IBD patients in remission experience
symptoms of IBS (e.g., abdominal pain and diarrhea in the
absence of active inflammation). It would be reasonable to
assume that brain-gut therapies for IBS can improve GI symp-
toms in those patients, though this has not yet been tested.
Hypnosis treatment has hardly been applied at all in IBD so
far in published work. The only controlled trial of that therapy
for IBD to date was remarkable, however, for being the first
study to demonstrate that a psychological intervention might
be able to influence disease activity in IBD. In that study
[48••], 54 ulcerative colitis patients in remission were random-
ized to either seven-session scripted hypnosis treatment spe-
cifically designed to prevent future disease flares, or equal-
length education intervention. The relapse rate after
12 months, which was the primary outcome, was significantly
lower in the hypnotherapy group: On average, the patients in
that group extended their remission periods by 78 days com-
pared to those in the education control group.
Recent Developments in Psychological
Brain-Gut Therapy Research
The two major developments apparent in the field of research
on psychological therapies for GI disorders in the last few
years are larger and better designed randomized controlled
trials than ever before, and steadily increasing efforts to de-
velop and test more efficient delivery formats. The latter is a
response to broad recognition that the psychological brain-gut
therapies are facing formidable practical obstacles that prevent
their wide use: They are hampered by limited scalability and
significant cost, because they require patients to complete a
series of individual treatment sessions delivered by highly
specialized mental health professionals who are mostly found
at specialty gastroenterology treatment centers. The great
majority of GI patients who could benefit from brain-gut ther-
apies do not have access to qualified therapists within a rea-
sonable commuting reach. And even where such services are
available, referrals for them are often reserved for unusually
severe patients or those who have proven unresponsive to
usual medical care approaches, due to the added cost of these
therapies and limited therapist manpower.
Efforts have been made on and off in recent years to test
alternative delivery modes that can help overcome these ac-
cessibility and cost hurdles. Those have most typically been
trials of either Internet-based therapy that requires little thera-
pist involvement [49–52], or of group therapy format [53, 54].
Several of these studies have shown very good promise, but
they have generally been relatively small and have not com-
pared those alternative methods directly to more traditional
therapist-delivered formats. That is now changing.
The three randomized controlled clinical trials that have
been published on CBT and hypnotherapy for GI disorders
in the last couple of years demonstrate both of these major
recent trends in the field: They were rigorously conducted
trials that constitute the largest ever RCTs for those respective
therapies and they each had direct comparison of alternative
therapy delivery modes to more traditional therapist-delivered
intervention as a main focus.
Everitt and colleagues in England just reported the findings of
the largest clinical trial [23••] ever conducted of CBT for GI
disorders. They randomly assigned 558 IBS patients to either
telephone-delivered CBT with a total of 8 h of therapist time,
or web-based CBT with 2.5 h of therapist support, or usual
medical treatment. Both CBT treatment delivery modes proved
significantly superior to usual medical treatment in terms of im-
provements in IBS severity, life impairment, and psychological
symptoms, and these benefits were well maintained at 12-month
follow-up. The authors also reported in a separate paper [28] that
24-month follow-up assessment showed continuingmaintenance
of the therapeutic gains of CBT patients, with some attenuation,
but it should be noted that only 58% of the patients reported their
symptom status at that time point.
In another substantial trial conducted in the USA [22],
Lackner et al. randomized 436 treatment-refractory IBS pa-
tients to either 10 sessions or 4 sessions of CBTwith a therapist,
with the latter treatment mode involving a more self-
administered intervention. They reported that the shorter thera-
py was as efficacious as the more traditional 10-session format,
and in fact it resulted in numerically higher responder rate post-
treatment (61% vs. 55%). Therapeutic effects of the CBT were
generally well maintained up to 12-month follow-up [55].
The largest controlled trial of hypnotherapy for GI disor-
ders to date [25], involving 354 primary and secondary care
IBS patients treated at 11 hospitals in the Netherlands, com-
pared outcomes for patients randomized to six-session courses
of either group hypnotherapy, individual hypnotherapy, or
group education about IBS. The treatment responder rate
was statistically superior for both hypnotherapy formats com-
pared to the control intervention: 40.8% in the individual hyp-
notherapy patients, 33.2% in those who received group hyp-
notherapy, and 16.7% in the control group. At 12 months,
those numbers were 40.8%, 49.5%, and 22.6% for the three
groups, and there was no significant difference between indi-
vidual and group therapy response rates at either time point.
Collectively, these three trials demonstrate clearly that
there are multiple viable methods to provide psychological
treatments for GI disorders in ways that require fewer therapist
hours per patient, while still having substantial and long-
lasting therapeutic impact.
Future Prospects and Priorities
In the last few years, the practice of psychological brain-gut
therapies and related GI-specialized psychological services has
come into its own as a health psychology sub-specialty and is
now increasingly referred to as psychogastroenterology [15].
Consensus is growing in this international group of practitioners
on effective clinical methods and best practices. It is a clinical
discipline that is highly empirically informed, relying on thor-
oughly tested methods developed by experts in the field. Due to
the large body of research on CBT and hypnosis, those treatment
modalities feature prominently in the clinical practice of
psychogastroenterology. These GI-specialized psychologists are
steadily growing in numbers, becoming integrated into gastroin-
testinal specialty care settings, and demonstrating the value they
can add in those environments [56–58].
I t seems vi ta l , however , in order for cl inical
psychogastroenterology to grow into amajor force that canmake
an overall difference in outcomes for GI patients in society, that
the research on ways to overcome cost and accessibility barriers
continue as a top priority, and that those lessons be promptly
implemented in clinical practice. Shortened therapy courses with
limited therapist involvement andmore self-administered therapy
tasks, remote therapy via phone or video conferencing, and group
treatment might become the standard ways of treating most GI
patients with brain-gut therapies, but more research is needed to
document the efficacy and best implementations of these ap-
proaches. Additionally, there are emerging options that have
barely been investigated yet in this research domain: In particular,
the possibility that entirely self-administered therapy might work
for some clinical applications or for certain patients, which could
make brain-gut therapies far more widely available. A number of
digital apps with cognitive behavioral and hypnotherapy content
for treating GI problems are now in development or undergoing
clinical testing, and a wave of published research on these is
likely in the near future. Additionally, training of psychologists
in the community outside specialty medical centers in applica-
tions of brain-gut therapies, thousands of who are already expe-
rienced in CBT and clinical hypnosis for other purposes, is also
an important practical way to broaden access for GI patients to
the benefits of these interventions.
Another essential task that psychogastroenterology research
must focus on to enable CBT and hypnotherapy to fully realize
their value as brain-gut therapies is to formally test their applica-
tion for more GI disorders. As seen from the summary above,
sufficient efficacy evidence only exists at present for both of
those therapies for IBS treatment and for CBT as treatment for
non-cardiac chest pain and for improving quality of life in IBD.
In clinical practice, on the other hand, GI-specialized psycholo-
gists are frequently using these therapies with good success for a
much wider range of GI presenting problems. To enable
evidence-based practice, empirical validation and tested proto-
cols for more GI health problems are needed. Furthermore, it is
important to develop and validate patient-reported outcomemea-
sures to be used as primary endpoints in psychogastroenterology
research with these disorders. Some of the additional treatment
targets where these brain-gut therapies are likely to prove of
value are globus and functional heartburn (hypnotherapy has
already demonstrated promising initial pilot results for both of
these [59, 60]), chronic constipation and diarrhea, functional
bloating/distention, and the functional nausea and vomiting
disorders.
With sufficient attention to these two priorities—
improving access and reducing cost, and empirical validation
of efficacy for more GI disorders—CBT and gut-directed hyp-
notherapy are poised to become increasingly valuable and
more widely available options for enhancing outcomes for
patients with the most challenging and common GI disorders
in the coming years.
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